1. Show article details.

    BRIEF-Nurix Therapeutics Announces Clearance Of Investigational New Drug Application For NX-1607 Supporting Plans To Expand Enrollment To U.S. Clinical Sites

    Reuters – 8:03 AM ET 06/30/2022

    Nurix Therapeutics Inc (NRIX): * NURIX THERAPEUTICS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NX-1607 SUPPORTING PLANS TO EXPAND ENROLLMENT TO U.S. CLINICAL SITES Source text for Eikon: Further company coverage:

  2. Show article details.

    Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

    GlobeNewswire – 8:00 AM ET 06/30/2022

    NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites in the U.S. SAN FRANCISCO, June 30, 2022 -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has received c...

  3. Show article details.

    Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

    GlobeNewswire – 7:00 AM ET 06/10/2022

    Nurix Therapeutics (NRIX), Inc. , a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress.

  4. Show article details.

    69 Biggest Movers From Friday

    Benzinga – 5:31 AM ET 06/06/2022

       

  5. Show article details.

    40 Stocks Moving In Friday's Mid-Day Session

    Benzinga – 12:07 PM ET 06/03/2022

     Gainers Turning Point Therapeutics, Inc. shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.  Losers Bit Origin Limited shares dipped 41.9% to $0.5001 after the company priced a 9,803,922 share offering at $0.51 per share.  

  6. Show article details.

    Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

    GlobeNewswire – 7:00 AM ET 06/03/2022

    Nurix Therapeutics (NRIX), Inc. , a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for three of its wholly-owned investigative therapies, NX-2127, DeTIL-0255 and NX-1607, each currently in Phase 1 development, at the Annual Meeting of the American Society of Clinical Oncology.

  7. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

    Benzinga – 10:02 AM ET 05/31/2022

    Guggenheim upgraded the previous rating for Novo Nordisk A/S from Neutral to Buy. According to Evercore ISI Group, the prior rating for Linde PLC was changed from In-Line to Outperform. For DISH Network Corp, Truist Securities upgraded the previous rating of Hold to Buy. According to Wells Fargo, the prior rating for Magellan Midstream Partners LP was changed from Equal-Weight to Overweight.

  8. Show article details.

    EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…

    Benzinga – 12:32 PM ET 05/27/2022

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma, Inc. is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with mCRPC who had progressed on two or more systemic therapies, including at least one second generation anti-androgen therapy.

  9. Show article details.

    Analyst Ratings for Nurix Therapeutics

    Benzinga – 12:10 PM ET 05/27/2022

    Within the last quarter, Nurix Therapeutics has observed the following analyst ratings: According to 4 analyst offering 12-month price targets in the last 3 months, Nurix Therapeutics has an average price target of $40.5 with a high of $60.00 and a low of $25.00. Below is a summary of how these 4 analysts rated Nurix Therapeutics over the past 3 months.

  10. Show article details.

    10 Biggest Price Target Changes For Friday

    Benzinga – 7:51 AM ET 05/27/2022

    Check out this: Meta And 3 Other Stocks Insiders Are Selling Don't forget to check out our premarket coverage here .

  11. Show article details.

    88 Biggest Movers From Yesterday

    Benzinga – 3:41 AM ET 05/27/2022

  12. Show article details.

    12 Health Care Stocks Moving In Thursday's Intraday Session

    Benzinga – 1:45 PM ET 05/26/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  13. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 12:15 PM ET 05/26/2022

      On Thursday, 94 companies set new 52-week lows. Stocks that set new 52-week lows on Thursday are as follows: Be sure to monitor Benzinga for the news traders need!

  14. Show article details.

    61 Stocks Moving In Thursday's Mid-Day Session

    Benzinga – 12:10 PM ET 05/26/2022

             

  15. Show article details.

    BRIEF-Nurix Therapeutics Announces Positive Dose Finding Data In Chronic Lymphocytic Leukemia And Advances Nx-2127 To Next Phase Of Clinical Development

    Reuters – 7:08 AM ET 05/26/2022

    Nurix Therapeutics Inc (NRIX): * NURIX THERAPEUTICS ANNOUNCES POSITIVE DOSE FINDING DATA IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ADVANCES NX-2127 TO NEXT PHASE OF CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage:

  16. Show article details.

    Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

    GlobeNewswire – 7:00 AM ET 05/26/2022

    Nurix Therapeutics (NRIX), Inc. , a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of NX-2127, an orally administered degrader of Bruton’s tyrosine kinase with immunomodulatory activity.

  17. Show article details.

    Nurix Therapeutics Doses First Patient in Phase 1a/1b Study of NX-5948 For B-cell malignancies

    Benzinga – 9:01 AM ET 05/17/2022

    Nurix Therapeutics, Inc. announced that the first patient has been dosed in the  Phase 1a/1b study to evaluate orally available small molecule NX-5948, in patients with relapsed B-cell malignancies.

  18. Show article details.

    BRIEF-Nurix Therapeutics Reports Dosing Of First Patient In Phase 1 Clinical Trial Of Nx-5948 In Development For B-Cell Leukemias And Lymphomas

    Reuters – 7:16 AM ET 05/17/2022

    Nurix Therapeutics Inc (NRIX): * NURIX THERAPEUTICS REPORTS DOSING OF FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF NX-5948, A SELECTIVE BTK DEGRADER, IN DEVELOPMENT FOR B-CELL LEUKEMIAS AND LYMPHOMAS. * Nurix Therapeutics Inc (NRIX) - TRIAL IS DESIGNED TO EVALUATE SAFETY AND TOLERABILITY OF NX-5948 IN ADULTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES.

  19. Show article details.

    Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

    GlobeNewswire – 7:00 AM ET 05/17/2022

    Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase in patients with relapsed B-cell malignancies.

  20. Show article details.

    Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

    GlobeNewswire – 4:02 PM ET 05/11/2022

    Nurix Therapeutics (NRIX), Inc. , a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18th, 2022 at 11:00 a.m. ET.

Page:

Today's and Upcoming Events

  • Jul
    11

    NRIX to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Apr
    07

    NRIX announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.